申请人:Purdue Pharma Ltd.
公开号:EP1288220A2
公开(公告)日:2003-03-05
The invention relates to a 3α-hydroxy, 17-(un)substituted derivatives of the androstane series and 3α-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at the recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having general structural formula (I), wherein R, R1, R2, R3,R4, R5, R6, R7, R8, R9 and R10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes pregnanes (R4 = methyl), 19-norandrostanes, and norpregnanes (R4=H).
本发明涉及一种 3α-羟基、17-(未)取代的雄甾烷系列衍生物和 3α-羟基、21-取代的孕烷系列衍生物。这些衍生物能够作用于最近确定的 GRC 上的位点,从而调节大脑的兴奋性,从而缓解压力、焦虑、失眠、适合 GRC 活性剂的情绪紊乱(如抑郁症)和癫痫发作活动。本发明的类固醇衍生物是具有通式(I)的衍生物,其中 R、R1、R2、R3、R4、R5、R6、R7、R8、R9 和 R10 在此进一步定义,虚线为单键或双键。该结构包括雄甾烷基孕烷(R4=甲基)、19-去雄甾烷基孕烷和去孕烷(R4=H)。